Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.
Live attenuated vaccines remain the safest, most cost-effective intervention against viral infections. Because live vaccine strains are generated empirically and the basis for attenuation is usually ill defined, many important viruses lack an efficient live vaccine. Here, we present a general strategy for the rational design of safe and effective live vaccines that harnesses the microRNA-based gene-silencing machinery to control viral replication. Using poliovirus as a model, we demonstrate that insertion of small miRNA homology sequences into a viral genome can restrict its tissue tropism, thereby preventing pathogenicity and yielding an attenuated viral strain. Poliovirus strains engineered to become targets of neuronal-specific miRNAs lost their ability to replicate in the central nervous system, leading to significant attenuation of neurovirulence in infected animals. Importantly, these viruses retained the ability to replicate in nonneuronal tissues. As a result, these engineered miRNA-regulated viruses elicited strong protective immunity in mice without producing disease.
Barnes
Dwight
D
Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143-2280, USA.
Kunitomi
Mark
M
Vignuzzi
Marco
M
Saksela
Kalle
K
Andino
Raul
R
D000818:Animals; D005818:Genetic Engineering; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000235:genetics*; D011051:Poliomyelitis / Q000628:therapy / Q000821:virology*; D017955:Poliovirus / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity / Q000502:physiology*; D011054:Poliovirus Vaccine, Inactivated / Q000235:genetics*; D018523:Tropism; D014779:Virus Replication
D035683:MicroRNAs; D011054:Poliovirus Vaccine, Inactivated
Nat Rev Genet. 2005 Mar;6(3):206-20
15703763
J Virol. 2005 Jan;79(2):1027-35
15613331
Cell. 2004 Apr 2;117(1):69-81
15066283
Nat Rev Genet. 2004 Jul;5(7):522-31
15211354
Nat Biotechnol. 2007 Dec;25(12):1457-67
18026085
Biologicals. 1997 Mar;25(1):3-15
9167004
Mol Cell. 2001 Mar;7(3):581-91
11463383
Genes Dev. 2007 Apr 1;21(7):744-9
17403776
Science. 2001 Aug 3;293(5531):834-8
11452083
PLoS Pathog. 2005 Oct;1(2):e11
16220146
J Virol. 2003 Nov;77(21):11531-5
14557638
Nature. 2001 Jan 18;409(6818):363-6
11201747
Mol Cell. 2004 Jul 23;15(2):185-97
15260970
EMBO J. 2002 Sep 2;21(17):4663-70
12198168
Cell. 2007 Jul 27;130(2):287-97
17662943
J Virol. 2005 Apr;79(7):4460-9
15767446
Nature. 2004 Nov 11;432(7014):231-5
15531879
Curr Biol. 2002 Apr 30;12(9):735-9
12007417
Nature. 2000 Feb 24;403(6772):901-6
10706289
Dev Cell. 2003 May;4(5):639-50
12737800
Nature. 2004 Sep 16;431(7006):356-63
15372043
Cell. 2005 Nov 18;123(4):621-9
16271385
Nature. 2006 Jan 19;439(7074):344-8
16327776
Science. 2005 Sep 2;309(5740):1577-81
16141076
Virus Res. 2004 Jun 1;102(1):65-74
15068882
Nat Med. 2006 May;12(5):585-91
16633348
J Virol. 2004 Mar;78(5):2601-5
14963165
Dev Cell. 2003 May;4(5):625-37
12737799
Nature. 2002 Jul 25;418(6896):430-4
12087357
J Virol. 1997 Oct;71(10):7841-50
9311872
Mol Cell. 2007 Aug 3;27(3):435-48
17679093
Nat Genet. 2006 Jun;38 Suppl:S25-30
16736021
J Gen Virol. 1997 Aug;78 ( Pt 8):1841-9
9266978
Nat Med. 2008 Feb;14(2):154-61
18246077
J Virol. 2005 Jun;79(11):7050-8
15890944
Cell. 2001 Jul 13;106(1):23-34
11461699
Genes Dev. 2007 Mar 1;21(5):531-6
17344415
Science. 2005 Apr 22;308(5721):557-60
15845854
Nature. 2003 Sep 25;425(6956):415-9
14508493
JAMA. 1999 Apr 28;281(16):1482-3
10227304
Mol Ther. 2008 Aug;16(8):1437-43
18560417
Trends Biotechnol. 2006 Apr;24(4):186-93
16503061
Trends Microbiol. 1999 Feb;7(2):76-82
10081085
Nature. 2004 Nov 11;432(7014):235-40
15531877
J Biol Chem. 2005 Jul 8;280(27):25706-16
15878882
Annu Rev Immunol. 2003;21:515-46
12500980
Cell. 2004 Jan 23;116(2):281-97
14744438